The overall response rate of this revolutionary cancer therapy named FUCASO is 96%. The NMPA’s approval marks a turning point in China’s fight against multiple myeloma. This blog explores the effectiveness of this therapy, its safety, and its potential to improve patient outcomes. Dive in and learn more about FUCASO and the hope it brings for refractory multiple myeloma patients.
Multiple myeloma, a blood cancer that affects plasma cells, can be a daunting opponent. It reduces immunity, and weakens bones, and, in spite of advances, it is still difficult to find long-term remedies. Multiple myeloma is estimated to affect approximately 176,404 people worldwide in 2020.
Multiple myeloma is the second most prevalent type of blood cancer, after lymphoma, yet it is still considered rare. It is more common in elderly people, with the average age of diagnosis being about 70. But there’s a ray of hope with advanced CAR T cell therapy in China!
China’s National Medical Products Administration (NMPA) recently approved a new BCMA CAR T cell therapy for cancer in China called FUCASO, marking a potential turning point in the fight against this complex disease. So, what is multiple myeloma, and why is FUCASO creating such excitement?
Recent studies show remarkable promise during trials, with an overall response rate of 96% and a complete response rate of 74.3% observed in 103 enrolled patients. This blog dives deeper into the science behind FUCASO, its potential impact on myeloma patients, and the hope it brings to the global fight against this challenging disease.
Is the high cost associated with cancer treatment making you feel overwhelmed with negative thoughts?
No need to worry more! Simply click here and discover free cancer treatment in China that is giving new hope to patients all over the world
What Is Multiple Myeloma Disease?
Multiple myeloma, often known as plasma cell myeloma or just myeloma, is a cancer of plasma cells, which are white blood cells found in the bone marrow. Plasma cells generally produce antibodies, which are proteins that help your body fight infections.
Plasma cells in multiple myeloma develop abnormally and multiply uncontrollably. These abnormal plasma cells crowd out healthy blood cells in the bone marrow, resulting in the production of abnormal M proteins.
Impact Of Multiple Myeloma On Human Body:
Bone damage: M proteins and abnormal plasma cells can damage bone tissue, leading to pain, fractures, and osteoporosis.
Kidney problems: M proteins can accumulate in the kidneys and impair their function.
Anemia: The crowding out of healthy blood cells by abnormal plasma cells can lead to anemia, causing fatigue and shortness of breath.
Weakened immunity: Abnormal plasma cells are unable to create normal antibodies, making the body vulnerable to infections.
The Science Behind FUCASO Treatment For Multiple Myeloma In China
FUCASO (Equecabtagene Autoleucel) is like a ground-breaking cancer treatment for complex cancer called multiple myeloma, especially for people whose cancer has come back after previous treatments (relapsed or refractory multiple myeloma, RRMM).
This special treatment uses the power of a person’s own immune system to fight cancer in a personalized and potentially curative way. In this treatment, the T cells are modified with special receptors called CARs (Chimeric Antigen Receptors), making them like guided missiles that can recognize and attack specific targets on cancer cells. FUCASO treatment for multiple myeloma in China is unique for a few important reasons:
Fully-Human: Unlike some similar treatments, FUCASO uses entirely human components, making it less likely to cause rejection and side effects.
BCMA-Specific: The CAR in FUCASO specifically targets BCMA, a protein that is highly present in myeloma cells. This accuracy reduces the amount of damage to healthy tissues.
Lentivirus As A Gene Vector: This is a highly efficient method for delivering genes to T cells. It allows T lymphocytes to recognize and destroy myeloma cells.
Powerful And persistent: FUCASO has been extensively tested and found to be highly effective and long-lasting in patients with multiple myeloma, giving hope for long-term remission.
China’s National Medical Products Administration (NMPA) recently gave the green light for FUCASO® to be used in treating multiple myeloma. Thanks to the efforts of Innovent Biologics and IASO Bio, this superhero-like treatment is now available, marking a big step forward in the fight against this challenging disease. This innovative treatment brings a fresh ray of hope for a brighter future
What Happened During The Trial Of FUCASO Treatment For Multiple Myeloma In China
The FUMANBA-1 clinical trial, conducted in China, examined the efficacy and safety of FUCASO (Equecabtagene Autoleucel) in patients with relapsed or refractory multiple myeloma (RRMM). The trial included 103 patients who each got a single dose of FUCASO, a CAR-T cell therapy for cancer in China.
The outcomes of this clinical study were truly impressive:
High response rate: 96% of patients responded to the treatment, with 74.3% attaining a severe complete response (sCR) or a complete response (CR), which means there were no identifiable cancer cells.
Rapid response: The median time to respond was only 16 days, showing a quick impact on the disease.
Durable remissions: At 12 months, 78.8% of patients were still progression-free, demonstrating the therapy’s long-term efficacy.
Deep remissions: 95% of patients achieved minimum residual disease (MRD) negative, which means there were very few undetectable cancer cells.
Effective in heavily treated patients: Even patients who had received prior CAR-T therapy responded well, with 9 achieving CR and 5 achieving sCR.
Positive safety profile: Only a few individuals encountered minor side effects such as cytokine release syndrome or neurotoxicity, and they all recovered well.
Persistence of therapy: At 12 and 24 months, FUCASO cells were detectable in a large proportion of patients, indicating the possibility of long-lasting action.
These data, presented at the American Society of Clinical Oncology meeting in 2023, indicate FUCASO’s promise as a very successful and well-tolerated multiple myeloma treatment.
What Is The Cost Of FUCASO Treatment For Multiple Myeloma In China?
Cost of FUCASO treatment for multiple myeloma in China is around $160,000 USD. While this may appear to be a large sum of money, it’s important to know that this treatment is a significant step forward in helping people with multiple myeloma.
It provides the opportunity for improved outcomes and a better life. If you are considering this therapy, it is a good idea to consult with your doctors or contact us for financial assistance if you are unable to pay the treatment cost.
The money spent on this new CAR T cell therapy in China is not just about paying for the treatment – it’s an investment in a new and better way to fight against multiple myeloma.
Best Hospitals For FUCASO Treatment For Multiple Myeloma In China
Let us help you discover some of the of the best hospitals in China that provide FUCASO treatment for multiple myeloma.
Peking University Cancer Hospital
Peking University Cancer Hospital is a well-known institute that is regarded as one of China’s best cancer treatment facilities. It is at the cutting edge of medical innovation, always pushing the boundaries of cancer research, diagnosis, and therapy.
Notably, Peking University Cancer Hospital is a pioneer in CAR T cell therapy, providing this sophisticated treatment option to patients facing a variety of cancers, including multiple myeloma.
So, if you’re considering CAR T cell therapy for multiple myeloma, this hospital is undoubtedly a reputable institution worth exploring.
Shanghai Changzheng Hospital
Changzheng Hospital, located in the heart of Shanghai, is a shining example of medical excellence, providing cutting-edge treatments such as CAR T cell therapy for a variety of blood cancers, including multiple myeloma.
Changzheng Hospital’s Department of Haematology leads the CAR T cell therapy program, using its years of expertise and superior equipment to provide personalized treatment programs.
Their dedicated team of hematologists, oncologists, and nurses work collaboratively to ensure each patient receives the highest quality care throughout the treatment journey.
Lu-Daopei Hospital
Dr. Lu Daopei, a famous hematologist, founded Lu-Daopei Hospital, which has established itself as a leader in blood disease treatment and research in China. Notably, they have substantial experience with CAR-T cell treatment, providing this revolutionary alternative to patients fighting multiple myeloma and other cancers.
They were the first in China to use CAR-T cells to treat B-cell acute lymphoblastic leukemia (B-ALL) and have since performed over 300 successful CAR-T procedures for various blood cancers.
Beijing Gobroad Boren Hospital
The hematology department at Beijing Gobroad Boren Hospital specializes in addressing hematological disorders with over thirty years of extensive experience in internal clinical and laboratory settings.
The department provides a full range of diagnostic and treatment services for illnesses such as multiple myeloma, leukemia, lymphoma, thalassemia, coagulation problems, and hematological tumors.
When it comes to treatment options, they offer a wide array of therapies for hematologic tumors, including: chemotherapy, immunotherapy, targeted therapy, and radiotherapy.
Reach Out To CancerFax For Multiple Myeloma Treatment Related Help
If you or a loved one is dealing with multiple myeloma, CancerFax is here to help. We’re like a friendly companion on your path to improved health.
CancerFax works with premier cancer hospitals across the world, including MD Anderson, Memorial Sloan Kettering, and the Mayo Clinic, to help patients seeking second opinions or specialized care get access to modern treatments.
For the past ten years, we’ve been helping people from more than 8 countries, and we’re ready to support you too. Contact us today to explore the best CAR T Cell therapy options in China and start your path to feeling better.
